Kate Cwynarski retweeted
A small study and ultimately negative, but important to see these data in PTCL (especially translational components) published! My take-home is that ctDNA is a promising adjunct to tissue diagnosis.
A phase IIa study of the anti-PD-L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL-T trial
onlinelibrary.wiley.com/doi/…
Kate Cwynarski retweeted
Congratulations to Dr Angelillp, @tcalimeri & co-authors on this extremely granular data of n=28 SCNSL patients treated with CAR-T, with impressive per-protocol 2y PFS of 66% in the infused (n=24) population. sciencedirect.com/science/ar…
Kate Cwynarski retweeted
Thanks to @Capt__Kirkwood for highlighting this study of accelerated step-up glofitamab including n=19 patients with CNSL (10 PCNSL, 9 SCNSL). No rates of Gr3+ ICANS seen, different from previous retrospective data where ICANS has been a concern...
doi.org/10.1002/hon.70270
Kate Cwynarski retweeted
Meta-analysis of 16 studies of allo v auto SCT for ENKTL:
- PFS and OS higher for auto
- Response rate higher for allo, but increased TRM
- Lots of heterogeneity between studies, except for OS estimates post auto (I² 0.1 in this group) & RR post allo
Allogeneic versus autologous stem cell transplantation for extranodal NK/T-Cell lymphoma: A systematic review and meta-analysis | Bone Marrow Transplantation share.google/4oNngoqubKnMWmt…
Kate Cwynarski retweeted
The Heterogeneous Landscape of Frontline Treatment of Peripheral T-Cell Lymphomas: A Systematic Review and Network Meta-Analysis
clinical-lymphoma-myeloma-le…
Kate Cwynarski retweeted
Although the approval rate from phase 1 trials in lymphoma is only 6.1%, heartening to see 8/45 approvals were in T-cell NHL from 2000 to 2019 - proportionate to its ~15% incidence
ashpublications.org/bloodadv…
Kate Cwynarski retweeted
A practical approach to risk stratification of incidental T-cell clonality ashpublications.org/bloodadv…
Kate Cwynarski retweeted
A phase IIa study of the anti-PD-L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL-T trial
buff.ly/DqnXj88
Kate Cwynarski retweeted
The incredible @ABarrettHaem receiving an abstract away at #ISHL14 for her work on older Hodgkin patients. Richly deserved. 👏👏👏
Kate Cwynarski retweeted
Efficacy and safety of tirabrutinib monotherapy for relapsed/refractory primary CNS lymphoma: PROSPECT phase 2 trial
ashpublications.org/blood/ar…
Kate Cwynarski retweeted
The global first step towards an anti-fibril in
Kappa AL Amyloidosis- anselamimab gets positive recommendations for approval in Japan - great work @AlexionPharma @SLentzsch @Amyloidosis_ARC @ISA_Amyloidosis
A phase IIa study of the anti-PD-L1 antibody avelumab in relapsed/refractory PTCL: The AVAIL-T trial
onlinelibrary.wiley.com/doi/…
Kate Cwynarski retweeted
Very useful data ! Congrats @ABarrettHaem 👏
New paper alert 👀 thank you to @Haematologica for publishing our analysis of ~30,000 UK classic Hodgkin lymphoma patients, with a focus on the ever-interesting older population. NB: anthracycline is key! haematologica.org/article/vi… @DavidJCutter @graham74GC
Kate Cwynarski retweeted
It’s nearly September so it’s nearly time for the national lymphoma management course! Do sign up and be educated, informed and hopefully inspired in lymphoma management.
Join our Lymphoma Management course this September! If you're a healthcare professional who has a role in managing patients with lymphoma, then this is the course for you! Hear from experts and advance your knowledge 👉 lymphoma-action.org.uk/event….
@graham74GC @tobyeyre82 #LymSM
ALT 'Lymphoma Management Expert education for professionals' written. Underneath in an orange outline with large quotation marks 'I’ll be teaching on why lymphoma is so interesting and the first-line management of patients with classical Hodgkin lymphoma. Professor Graham Collins' is written.
Kate Cwynarski retweeted
British Journal of Haematology | Wiley Online Library. @CwynKate onlinelibrary.wiley.com/doi/…
Kate Cwynarski retweeted
Ready to take your next step in clinical research? Applications for CRTH are now open.
The Clinical Research Training in Hematology (CRTH) program is a nine-month training and mentoring experience designed for early-career hematologists who want to grow as clinical researchers.
Successful applicants will be trained and coached by top-tier experts in their field, who will help you develop your knowledge and skills in clinical science through mentoring and training during two multi-day workshops and a session at the EHA Congress.
Learn more about CRTH and apply by September 15, 2026 (15:00 CEST): eha.fyi/CRTH_2027
Kate Cwynarski retweeted
EHA CRTH was a gamechanger for me, academically and personally. Watch the whole interview to get my insights and takes.
If you are interested to pursue a career in clinical research contact me directly!
What does it take to turn a research idea into a clinical trial?
In the latest episode of EHA Unplugged, Prof @EliasKarlMai shares his journey from clinical practice to becoming a principal investigator, including the role that EHA's Clinical Research Training in Hematology (CRTH) program played along the way.
If you're an early-career hematologist looking to strengthen your clinical research skills, expand your network, and learn from experienced mentors, CRTH could be your next step. Applications for the 2027 cohort are open until September 15, 2026 ( CEST).
Listen to the episode and discover where a career in clinical research can take you: tr.ee/K2uCZuNpqq
Kate Cwynarski retweeted
What does it take to turn a research idea into a clinical trial?
In the latest episode of EHA Unplugged, Prof @EliasKarlMai shares his journey from clinical practice to becoming a principal investigator, including the role that EHA's Clinical Research Training in Hematology (CRTH) program played along the way.
If you're an early-career hematologist looking to strengthen your clinical research skills, expand your network, and learn from experienced mentors, CRTH could be your next step. Applications for the 2027 cohort are open until September 15, 2026 ( CEST).
Listen to the episode and discover where a career in clinical research can take you: tr.ee/K2uCZuNpqq
Kate Cwynarski retweeted
A multicentre phase III clinical trial of dual-epigenetic therapy plus CHOP compared with CHOP in previously untreated patients with peripheral T-cell lymphoma
nature.com/articles/s41408-0…
Kate Cwynarski retweeted
Congratulations to the authors of the ph3 'MATRix'/IELSG43 trial - the largest randomised trial in PCNSL to date - definitively demonstrating the benefit of thiotepa-ASCT over non-myeloablative chemotherapy post MATRix induction, including a OS benefit. thelancet.com/journals/lance…